Granules India Ltd News

Granules India gets US regulator FDA's approval for generic ADHD drug

Drug firm Granules India on Tuesday said its subsidiary has received approval from the US health regulator for a generic medication used to treat attention-deficit hyperactivity disorder. Granules Pharmaceuticals, Inc (GPI) has received approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Lisdexamfetamine Dimesylate chewable tablets, the drug firm said in a statement. The approved drug is available in multiple strengths; 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, and 60 mg, it added. The company's product is the generic equivalent to Takeda Pharmaceuticals' Vyvanse chewable tablets, the company said. The medication is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in adults and pediatric patients aged six years and older, as well as moderate to severe binge eating disorder (BED) in adults. Lisdexamfetamine dimesylate chewable tablets are currently published on the FDA Drug Shortages List, emphasising ..

FIIs turn bullish on Nifty; F&O activity hints at gains ahead

Cues from F&O market for December 10: Foreign investors are seen building long positions in Nifty futures thus far this month, with open interest rising by 27% in the last six days.

Granules India share tanks 10% after USFDA's 'OAI' tag for Gagillapur Unit

The fall in Granules India share price came after the company announced that United States Food and Drug Administration (USFDA) has classified the inspection of Gagillapur unit as OAI

Max pain for Bank Nifty seen at 50,900; bias seems cautiously positive

F&O cues for Nov 22: Bank Nifty formed a hammer candlestick pattern on Thursday; trade above 50,650 levels can trigger a pullback towards 51,000 - 51,500 levels, says analyst from Asit C Mehta.

Options data hint at bearish bias for Nifty, Bank Nifty; FIIs trim shorts

F&O cues for Nov 21: Foreign investors open interest in Bank Nifty futures declined over 9 per cent as they net bought nearly 25,000 contracts on Tuesday, shows the NSE F&O data.

Can Nifty snap its 7-day losing streak today? Here's what F&O data suggests

F&O cues for Nov 19: Rising Call-writing across 23,500-24,000 range underscores seller dominance, while diminishing Put-writing reflects cautious sentiment, said Dhupesh Dhameja of SAMCO Securities.

F&O data shows Nifty pivot at 23,550; Can Bank Nifty trigger a pull-back?

F&O cues for Nov 18: As long as Bank Nifty holds the 200-DEMA support near 49,900, the index could witness a pullback move towards 50,500-50,600 levels, believes Hrishikesh Yedve of Asit C. Mehta.

FIIs add short positions in Nifty, Bank Nifty; OI rises up to 75% in Nov

F&O cues for Nov 14: Nifty has dipped nearly 3% thus far in Nov series, with FIIs holding short positions in 3:1 ratio; while retail investors holding bullish bets at 2:1 in index futures, shows data.

Nifty remains trapped in 24,000-24,500 range; probability of bounce higher

F&O cues for Nov 12: Options data hint support for Nifty at 23,950; with a high probability of a bounce back towards 24,500 - 24,700; says Sahaj Agarwal of Kotak Securities.

Nifty rebound attempt fizzles, sellers reinforce resistance; shows F&O data

F&O cues for Nov 11: Nifty's outlook has shifted to a bearish-to-sideways bias, as multiple rally attempts have been thwarted by sellers, says Dhupesh Dhameja of SAMCO Securities.

FIIs add fresh shorts in Nifty futures; F&O data hints at cautious stance

F&O cues for Nov 08: According to the options data, the max pain level for the Nifty now stands at 24,200, and for Bank Nifty at 52,100; says Dhupesh Dhameja of SAMCO Securities.

Nifty futures premium erodes; options hints at more pain below 24,700

F&O cues for Oct 22: Breakout from 24,700-25,250 range to trigger the next directional move, said Sahaj Agarwal of Kotak Securities. IndiaMart InterMesh and RBL Bank among 16 stocks in F&O ban today.

Nifty resistance stands at 25,000-mark; Bias for Bank Nifty turns positive

F&O cues for Oct 21: Despite Friday's recovery, Nifty options continues to reflect cautious sentiment, with call writing outweighing put writing on Friday, said Dhupesh Dhameja of SAMCO Securities.

Pivot point for Nifty 50 index moves higher to 25,150, suggests F&O data

Derivatives market update Oct 15: In case of Bank Nifty the max pain is seen at 51,800; with the PCR rising to 1 - tilt towards a bullish bias is observed, says SAMCO Securities analyst.

Check FII, Retail, Proprietary trading bets in F&O at the start of the week

Derivatives market update Oct 14: The Nifty weekly options data shows a tug-of-war between the bulls and the bears at the 25,000 Strike Price. FIIs continue to hold notable shorts in Bank Nifty.

F&O Alert: FIIs net sell 3.5 lakh Nifty, Bank Nifty futures in just 3 days

Derivatives market update Oct 08: FIIs turn bearish on Indian stocks, long-short ratio in index futures dipped below 1 for the first time since August 14. Retail and proprietary trades turn bullish.

FIIs unwind Nifty longs, add shorts in Bank Nifty; Experts see more pain

Derivatives market update for Oct 04: Data shows Balrampur Chini, Dabur, Bata India, Reliance, Axis Bank and Manappuram Finance are few of the F&O stocks that saw short build-up on Thursday.

FIIs most bullish in 3 months, shows F&O data; Nifty eyes 4th monthly gain

Derivatives market update for Sept 30: FIIs long-short ratio in index futures jumped to 4.4:1; implying more than 4 long positions in index futures for every bet on the short side.

Granules, GCPL, RECL among 4 F&O stocks with bearish bets; more pain likely

F&O Cues: Granules India has shed 20.8% on the back of 78% increase in OI in the last four days; here's a trading guide for stocks with short buildup in the September series.

F&O Insights: Nifty, Bank Nifty premium rises, PCR dips; check key levels

Derivatives market update for Sept 17: The premium in Nifty Sept futures jumped to 58 pts, and Bank Nifty to 100 pts; whereas, the PCR declined to near 1 levels indicating positive to sideways trend.